<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1075">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02868905</url>
  </required_header>
  <id_info>
    <org_study_id>2015-A01686-43</org_study_id>
    <nct_id>NCT02868905</nct_id>
  </id_info>
  <brief_title>Identification of Epigenetic Markers Common to Obesity and Alzheimer's Disease in Women</brief_title>
  <acronym>Oba</acronym>
  <official_title>Identification of Epigenetic Markers Common to Obesity and Alzheimer's Disease in Women - Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central Hospital, Nancy, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Central Hospital, Nancy, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare average methylation of epigenetic markers on genomic&#xD;
      DNA and some genes (APP, BACE, LRP, SorL1) involved in cerebral amyloid homeostasis:&#xD;
&#xD;
        -  Of obese young adults and healthy young adults&#xD;
&#xD;
        -  Of obese young adults and individuals affected by Alzheimer's disease (AD) having been&#xD;
           obese at young adult age (&lt;50 years old) or individuals affected by Alzheimer's disease&#xD;
           (AD) having never been obese.&#xD;
&#xD;
      The secondary purpose is to determine if there is an association between the frequency of&#xD;
      these epigenetic markers and elements associated to the metabolic syndrome (lipidic and&#xD;
      glycemic analysis, leptinemia, inflammation markers) and clinical ones (visceral fat mass,&#xD;
      body mass index) in young adults.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Methylation of CpG islands in genomic DNA and in 4 target genes involved in AD (APP, SorLA/LR11, BACE1, LRP) in obese and AD subjects</measure>
    <time_frame>day 0</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>body mass index</measure>
    <time_frame>day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>visceral fat mass level</measure>
    <time_frame>day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>leptinemia by ELISA</measure>
    <time_frame>day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>insulinemia by ELISA</measure>
    <time_frame>day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>glycemia</measure>
    <time_frame>day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>triglyceridemia</measure>
    <time_frame>day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HDL cholesterol level in blood</measure>
    <time_frame>day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reactive C protein level in blood</measure>
    <time_frame>day 0</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Obesity</condition>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Control group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Obese group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Obese group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-obese AD group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Non-obese AD groups</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Obese AD group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Obese AD group</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood sample</intervention_name>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Non-obese AD group</arm_group_label>
    <arm_group_label>Obese AD group</arm_group_label>
    <arm_group_label>Obese group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Group 1:&#xD;
&#xD;
          -  18-50 year old women, age- (10 years) and sociocultural-matched with group 2&#xD;
&#xD;
          -  Non obese and never been obese&#xD;
&#xD;
          -  18.5 &lt; BMI &lt; 25&#xD;
&#xD;
          -  Folstein MMS &gt; 27&#xD;
&#xD;
          -  Informed consent&#xD;
&#xD;
          -  Affiliation to social security plan&#xD;
&#xD;
        Group 2:&#xD;
&#xD;
          -  18-50 year old women, age- (10 years) and sociocultural-matched with group 1&#xD;
&#xD;
          -  Waist size &gt; 88cm&#xD;
&#xD;
          -  30 &lt; BMI &lt; 45&#xD;
&#xD;
          -  Insulin-resistant patients (Insulin resistance index, HOMA-IR &gt; 3.8)&#xD;
&#xD;
          -  Obesity onset during childhood (pre-puberty period)&#xD;
&#xD;
          -  Folstein MMS &gt; 27&#xD;
&#xD;
          -  Informed consent&#xD;
&#xD;
          -  Affiliation to social security plan&#xD;
&#xD;
        Group 3:&#xD;
&#xD;
          -  &gt;60 year old women, age- (10 years) matched with group 4&#xD;
&#xD;
          -  No obesity history (18.5 ≤ BMI &lt; 25 at adult age)&#xD;
&#xD;
          -  Sporadic forms of mild to moderate AD with demonstration of AD physiopathologic&#xD;
             process according to new recommendations of 2011 of National Institute on Aging and&#xD;
             Alzheimer's Association on diagnostic guidelines for Alzheimer's disease&#xD;
&#xD;
          -  15&lt; Folstein MMS ≤ 26&#xD;
&#xD;
          -  Informed consent&#xD;
&#xD;
          -  Affiliation to social security plan&#xD;
&#xD;
        Group 4:&#xD;
&#xD;
          -  &gt;60 year old women, age- (10 years) matched with group 3&#xD;
&#xD;
          -  Obesity history (BMI &gt; 30 at least one time at adult age)&#xD;
&#xD;
          -  Sporadic forms of mild to moderate AD with demonstration of AD physiopathologic&#xD;
             process according to new recommendations of 2011 of National Institute on Aging and&#xD;
             Alzheimer's Association on diagnostic guidelines for Alzheimer's disease&#xD;
&#xD;
          -  15 &lt; Folstein MMS ≤ 26&#xD;
&#xD;
          -  Informed consent&#xD;
&#xD;
          -  Affiliation to social security plan&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Group 1:&#xD;
&#xD;
          -  &lt;18&#xD;
&#xD;
          -  Patient under guardianship, curatorship or judicial protection&#xD;
&#xD;
          -  Folate supplementation&#xD;
&#xD;
          -  Diabetic or glucose intolerant subjects&#xD;
&#xD;
          -  Present participation to another study with neuropsychological evaluation and/or drug&#xD;
             administration&#xD;
&#xD;
          -  Pregnant women&#xD;
&#xD;
        Groups 2,3 and 4:&#xD;
&#xD;
          -  &lt;18&#xD;
&#xD;
          -  Patient under guardianship, curatorship or judicial protection&#xD;
&#xD;
          -  Folate supplementation&#xD;
&#xD;
          -  Present participation to another study with neuropsychological evaluation and/or drug&#xD;
             administration&#xD;
&#xD;
        Group 2:&#xD;
&#xD;
        - Pregnant women&#xD;
&#xD;
        Group 4:&#xD;
&#xD;
        - Obese or overweight patients (BMI&gt;25)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thérèse RIVASSEAU-JONVEAUX</last_name>
    <role>Principal Investigator</role>
    <affiliation>Service de Gériatrie, Hôpitaux de Brabois, 3 rue du Morvan, 54 511 Vandoeuvre-lès-Nancy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Thérèse RIVASSEAU-JONVEAUX, Dr</last_name>
    <email>t.jonveaux@chru-nancy.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHRU de Nancy</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <study_first_submitted>August 11, 2016</study_first_submitted>
  <study_first_submitted_qc>August 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 16, 2016</study_first_posted>
  <last_update_submitted>August 11, 2016</last_update_submitted>
  <last_update_submitted_qc>August 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

